Rockville, Maryland, United States – September 7, 2026 – New 2026 research using longitudinal Fitbit wearable data, electronic health records, and genetic risk information found that physical activity and sleep patterns were associated with the risk of incident major depressive disorder, highlighting the growing role of continuous digital measurements in psychiatric research. The study analyzed wearable data from more than 3,000 adults and found that combining longitudinal behavioral signals with inherited-risk information improved risk discrimination.

According to Fact.MR, the global psychiatric digital biomarkers market is valued at USD 1.5 billion in 2026 and is projected to reach USD 5.7 billion by 2036, expanding at a 14.3% CAGR. The market was valued at USD 1.3 billion in 2025, creating an estimated absolute opportunity of USD 4.2 billion during the forecast period.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15861

Why Continuous Measurement Matters in Psychiatry

Psychiatric symptoms can fluctuate substantially between scheduled clinical appointments. Sleep disruption, reduced activity, changes in speech, altered social behavior, and physiological responses may occur before a patient reports a deterioration during a clinical assessment.

Digital biomarkers provide a potential way to capture those changes continuously.

Wearables can collect activity, sleep, temperature, skin conductance, and pulse-derived signals. Smartphones can contribute passive behavioral information, while voice and speech technologies can assess features associated with mood and emotional state. Cognitive assessment tools can add another layer of measurement.

For pharmaceutical sponsors, the value is particularly relevant to clinical investigations. For hospitals, the commercial proposition is different: digital signals must fit into existing documentation, escalation, privacy, and clinical-accountability processes.

The market therefore is moving beyond data collection toward validated measurement linked to a defined clinical or development decision.

Wearable-Based Biomarkers Hold the Largest Product Share

Wearable-based digital biomarkers are projected to account for 31.0% of the market in 2026, making them the leading product category.

Wearables offer repeated measurement with limited daily effort from patients. Smartwatches and wristbands can capture physiological and behavioral signals without requiring users to complete questionnaires throughout the day.

Their value, however, depends on interpretation. A sensor does not become a clinically useful biomarker simply because it generates large volumes of data.

Validation must establish what a signal measures, how consistently it performs across populations, how missing data are handled, and how clinicians should act on the output.

This is becoming a practical procurement issue for hospitals and pharmaceutical companies evaluating digital biomarker suppliers.

Depression Monitoring Leads Application Demand

Depression Monitoring is expected to hold 32.0% of the market in 2026, the largest application share.

Major depressive disorder and related conditions can involve changes in sleep, movement, activity, speech, cognition, and social behavior. Longitudinal digital measurement can potentially provide greater temporal resolution than periodic symptom assessments.

The opportunity extends beyond detecting symptoms. Digital biomarkers may support treatment-response monitoring, relapse prediction, patient stratification, and clinical-trial endpoint development.

The recent wearable-based MDD research reinforces this direction. Researchers found that combining polygenic risk with longitudinal wearable features improved model discrimination compared with progressively simpler data combinations. The findings remain research evidence rather than a validated clinical diagnostic tool, but they demonstrate the type of multimodal analysis now being explored.

“Psychiatric digital biomarkers will earn budget only when they change a clinical or development decision,” said Shambhu Nath Jha, Principal Consultant at Fact.MR. “Buyers need validated endpoints, clear performance limits, demographic generalizability, and ownership of escalation.”

Hospitals Represent the Largest End-User Segment

Hospitals are projected to capture 34.0% of the market in 2026.

The hospital segment benefits from established clinical governance and the ability to integrate psychiatric monitoring into behavioral-health, neurology, emergency, and post-discharge workflows.

The requirement for governance is also a market restraint. A false-positive signal can increase alert burden, while false reassurance can delay intervention. Privacy, interpretability, calibration, demographic performance, and integration therefore become part of the purchasing decision.

This shifts competition away from feature count. Vendors must demonstrate that their systems can operate reliably within real clinical environments.

Multimodal Programs Create the Clearest Opportunity

Fact.MR identifies multimodal enterprise programs as the clearest commercial opportunity.

A multimodal platform can combine wearable physiology, smartphone behavior, voice characteristics, and cognitive assessments. Each data stream has limitations, but combining signals can provide greater resilience when one source is incomplete or noisy.

For enterprise buyers, the practical requirement is to define the pathway first.

A hospital needs to know who receives an alert, what threshold triggers escalation, how the event is documented, and whether the patient's care team has responsibility for responding.

Pharmaceutical sponsors face a similar question during clinical development: which specific trial decision will the digital endpoint influence?

These operational details can determine whether a digital biomarker becomes a recurring enterprise purchase or remains a research demonstration.

Germany Leads Country Growth

Germany is forecast to expand at 16.4% CAGR from 2026 to 2036, the fastest growth rate among the countries profiled by Fact.MR.

Germany's digital-health reimbursement framework provides a formal pathway from qualifying digital evidence to paid use, while effectiveness, data protection, and medical-purpose documentation remain important requirements.

Brazil follows at 15.0% CAGR, supported by increasing enterprise interest and the need to distinguish regulated medical-purpose software from wellness tools.

The United States is projected to grow at 13.6% CAGR, with demand concentrated in pharmaceutical development and health-system purchasing.

Australia is forecast at 13.2%, Canada at 12.8%, the United Kingdom at 12.2%, and Japan at 10.7% during 2026–2036.

Competitive Landscape

The competitive landscape includes Koneksa, Biofourmis, Mindstrong Health, Empatica, Altoida, Rune Labs, BeCare Link, Sonde Health, Feel Therapeutics, and Winterlight Labs. Fact.MR identifies Koneksa and Biofourmis as leading companies.

Competition is divided between enterprise measurement infrastructure, psychiatric signal specialists, and cognitive or behavioral assessment providers.

Empatica received FDA 510(k) clearance in November 2023 for pulse and respiratory-rate biomarkers on its health-monitoring platform. Feel Therapeutics launched its Feel Monitor in June 2024, combining a wearable with an AI platform for emotional and mental-health monitoring. Sonde Health has focused on voice-based analysis, using smartphone recordings to extract vocal features associated with mental-health conditions.

The market's next competitive threshold will be evidence quality, workflow integration, and repeatable enterprise deployment rather than sensor availability alone.

Psychiatric Digital Biomarkers Market Snapshot

2025 market value: USD 1.3 billion
2026 market value: USD 1.5 billion
2036 projected value: USD 5.7 billion
CAGR, 2026–2036: 14.3%
Absolute opportunity: USD 4.2 billion
Leading product type: Wearable-Based Digital Biomarkers, 31.0%
Leading application: Depression Monitoring, 32.0%
Leading end user: Hospitals, 34.0%
Fastest-growing profiled country: Germany, 16.4% CAGR
Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/report/psychiatric-digital-biomarkers-market

Report Scope and Methodology

The Fact.MR study covers psychiatric digital biomarker platforms and associated enterprise services used to capture, analyze, and interpret mental-health-related signals.

The scope includes wearable-based biomarkers, smartphone-based biomarkers, voice and speech biomarkers, behavioral biomarker platforms, and multimodal solutions. Applications include depression monitoring, anxiety disorder management, schizophrenia monitoring, bipolar disorder management, and cognitive and behavioral assessment.

The study excludes downstream drug revenue, general telepsychiatry without biomarker measurement, wellness-only applications, and non-psychiatric biomarker revenue.

Fact.MR combines primary research with desk research, bottom-up revenue estimates, top-down market checks, buyer adoption analysis, deployment and renewal patterns, country-level conditions, and source triangulation.

Explore More Related Studies Published by Fact.MR Research

Health Economics and Outcomes Research Services Market- https://www.factmr.com/report/health-economics-and-outcomes-research-services-market

Healthcare Agentic Artificial Intelligence Market- https://www.factmr.com/report/healthcare-agentic-artificial-intelligence-market

Healthcare AI Consulting Services Market- https://www.factmr.com/report/healthcare-ai-consulting-services-market

Healthcare and Medical Devices Testing Inspection and Certification Market- https://www.factmr.com/report/healthcare-and-medical-devices-testing-inspection-and-certification-market

Healthcare Computerized Maintenance Management System Market- https://www.factmr.com/report/healthcare-computerized-maintenance-management-system-market

About Fact.MR

Fact.MR is an initiative of Eminent Research and Advisory Services, providing market intelligence and syndicated research across healthcare, food and beverage, consumer goods, technology, industrial goods, and other sectors. The company operates from offices in Rockville, Maryland, United States, and Dublin, Ireland.

Media Contact

Fact.MR
11140 Rockville Pike, Suite 400
Rockville, MD 20852, United States
Tel: +1 (628) 251-1583
Email: [email protected]

Suite 9884, 27 Upper Pembroke Street
Dublin 2, Ireland
Tel: +353-1-4434-232

Disclosure

This release is based on Fact.MR syndicated research. Market figures represent estimates and forecasts available as of the publication date and may be revised as additional information becomes available.